Empowering biotech innovations: End-to-end solutions for your immunotherapy trials
A U.S.-based biotech company developing an intratumoral immunotherapy for a Phase I study had primarily relied on in-house teams and niche providers. This case study highlights how Fortrea went beyond traditional support, offering operational and scientific guidance to reshape the protocol, co-develop strategies, and optimize the clinical approach.
